Technology offer : Development of a second generation candidate vaccine against human and canine leishmaniasis

Technology's description

Leishmaniasis are serious parasitic infection affecting Humans in 88 countries. 350 million people are exposed and 16 million are carriers of the parasite. There is between 2 and 2.5 million new cases each year: more than 500 000 of which are visceral leishmaniasis (the most severe form) and 1.5 to 2 million are cutaneous leishmaniasis (90% of cases are located in 8 countries: Afghanistan, Algeria, Tunisia, Brazil, Iran, Peru, Saudi Arabia and Syria).

These diseases are still a real public health problem in Latin America, Asia, Africa and Southern Europe.

 

In the absence of effective treatment against leishmaniasis and the extent of this public health problem in many part of the world, it is important to provide affected populations with a large-scale preventive: the most suitable would be vaccination. However, observation remains current: there is no vaccine available against human leishmaniasis.

The proposed technology consists of the composition of a multi-epitopic multivalent peptide vaccine for human purposes.



Advantages

  • Vaccine based on synthetic peptides (good safety, chemically well defined, modifiable sequence to increase immunogenicity)
  • Easy and low cost production
  • Thermostable
Ref : OT-00106

Area of activity : HEALTH COSMETOLOGY

Download pdf

Industrial applications

  • Control against leishmaniasis

Intellectual property

  • Patents

Technology transfer

  • Co-development with licensing agreement

CONTACT


Vanessa ZEPPONI
Business developer

vanessa.zepponi@cvt-sud.fr
P: +33 (0)4 91 99 94 27